Grouping and Bundling of Medical Device Authorization Applications in Ethiopia

1. Key takeaways

Ethiopia allows multiple devices to be combined into a single marketing authorization application, officially termed Grouping or Bundling. Six forms are available: Single, Family, Set, System, IVD Cluster and IVD Test kit. The grouping criteria are divided between general criteria applicable to all devices and device-specific criteria, laid down in two separate guidelines. The grouping approach directly determines future variation frequency and cost — it is a cost-structure question, not a form-filling technique.

The economic logic is easy to state and easy to underestimate. A first registration organized into well-chosen groups carries fewer application fees and fewer parallel files; but the same grouping choice fixes the perimeter within which every future variation, renewal and lifecycle decision will operate. A perimeter drawn too tightly multiplies files forever; one drawn too loosely makes every model change drag the whole group into review. The grouping decision is therefore made once, at the first filing, and paid for — in either direction — for the entire life of the portfolio.

2. Legal basis

3. Expert insights

Insight 1: the reason a grouping system exists comes from the complexity of devices themselves. Section 5.2 of the general guidelines notes that devices range from the simple (such as syringes) to the highly complex (such as implantable pacemakers), and include products assembled from numerous components (such as patient monitoring systems); these components or modules can be sold separately, combined as needed, delivered as integrated kits, or packaged to order; and an individual device itself comes in multiple configurations of length, diameter and the like. Without grouping rules, a single technology platform would be split into hundreds of separate applications. The grouping framework is the regulatory answer to combinatorial complexity, not a convenience concession.

Insight 2: the six forms correspond to different product organization logics. Single covers one device; Family covers multiple models under one design; Set covers several devices sold together as a package; System covers several components used in combination; IVD Cluster covers multiple assays under one methodology; and IVD Test kit covers a complete testing solution containing reagents, calibrators and controls. Choosing the wrong form leads to a request to split the application at review. The forms are not interchangeable containers: each encodes a specific technical relationship, and the review examines whether the claimed relationship actually holds.

Insight 3: device-specific attributes change the grouping outcome. The general guidelines make explicit that certain device-specific attributes — such as those particular to in vitro diagnostic devices and hearing aids — must be taken into account when classifying products into groups. This confirms that the general criteria cannot cover every situation: for IVDs and other special categories, the device-specific grouping principles must be consulted before the grouping architecture is fixed. A grouping plan drafted only from the general rules is provisional at best for these categories.

Insight 4: grouping is both a compliance dividend at first registration and a constraint on future changes. Filing multiple models as one Family can significantly reduce first-round registration costs and fees; but a variation to any model within the Family may affect the validity of the entire group, and adding a new device category generally requires a separate variation procedure. The granularity of the bundling should therefore be designed deliberately at the first filing. The optimum is rarely the largest possible group; it is the group whose internal variation behavior is genuinely shared.

Insight 5: the spread from simple to complex devices means the grouping justification needs technical, not commercial, input. The justification materials must explain the commonalities and differences in design, intended use and technical characteristics; the work is completed jointly by the regulatory and technical departments, and cannot be a simple SKU listing assembled by the sales department. Where the technical basis of a claimed family is thin, the reviewer’s first question is which characteristic actually links the models — and an answer grounded in commercial logic rather than design data will not survive it.

4. Practical recommendations

1. Organize grouping around technical commonality, not SKUs: prefer the Family and System forms where they genuinely fit.
2. For IVD assays prefer the Cluster and Test kit forms: match the grouping to the methodology.
3. Consult the device-specific principles in EFDA-GDL-093 before grouping: especially for IVDs.
4. Design the bundling granularity in one pass: reduce future variation costs from the start.
5. State the grouping basis and form in the application letter: it helps classification at the screening stage.
6. Maintain a grouping ledger: record the group membership of every model to support variation management.

5. Verification checklist

• □ Grouping form determined (Single / Family / Set / System / IVD Cluster / IVD Test kit)
• □ Grouping justified on the basis of technical commonality
• □ Device-specific grouping principles in EFDA-GDL-093 consulted
• □ Grouping basis stated in the application letter
• □ Grouping ledger established to support future variation management

Regulatory information verified as of October 29, 2026. The grouping forms and criteria sources described in this article follow Section 5.2 of EFDA-GDL-046 and the current text of EFDA-GDL-093; when the guidance is updated, the content must be re-verified.

• Ethiopia local resource: GRZAN supports manufacturers from the Chinese mainland and overseas in working with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA) applications, the institutional competency certificate (CoC) and import permit applications, including local agent scheme design and agency agreement review, SRA reliance route justification, UMDN coding and classification determination, technical dossier preparation, and vigilance and post-market surveillance system setup.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility determination, Essential Principles conformity justification, English-language labeling and instructions-for-use localization, vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn. For EFDA registration pathway and classification strategy support for the Ethiopian market, write to info@grzanglobal.com.